US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Propanc Biopharma, Inc.

1.35

-0.8800-39.46%

Post-market: 1.34-0.0100-0.74%19:59 EDT

Volume:4.06M

Turnover:6.74M

Market Cap:4.73M

PE:-0.04

High:1.94

Open:1.93

Low:1.31

Close:2.23

52wk High:81.00

52wk Low:0.9500

Shares:3.50M

Float Shares:1.25M

Volume Ratio:0.21

T/O Rate:324.53%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-32.4560

EPS(LYR):-371.2241

ROE:-126.98%

ROA:-62.31%

PB:0.48

PE(LYR):0.00

Loading ...

Overview Company News Filings

Propanc Biopharma - Mou to Support Phase 1B First-in-human Trial for Propanc's Prp

THOMSON REUTERS

Propanc Biopharma Signs Mou with Avance Clinical Pty Ltd

THOMSON REUTERS

Propanc Biopharma Initiates $5.0 Million Share Repurchase Program

THOMSON REUTERS

Propanc CEO visits European manufacturer ahead of drug production plan

Propanc Biopharma CEO tours European CDMO GMP facility ahead of PRP production for Phase 1b study

Top Midday Gainers

MT Newswires Live

Propanc Biopharma Authorizes $5 Million Stock Buyback Program; Shares Jump

MT Newswires Live

Propanc Biopharma launches USD 5 million share buyback program

Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program

THOMSON REUTERS

Top Premarket Gainers

MT Newswires Live

Propanc Biopharma CEO attends University of Granada keynote on rejuvenation science

Propanc Biopharma plans Phase 1b first-in-human PRP trial in Australia in 2026

Propanc Biopharma Inc - to File Cta in Australia for Phase 1B Study in 30–40 Advanced Cancer Patients

THOMSON REUTERS

Propanc Biopharma Inc - Plans Two Phase 2 Studies in Pancreatic and Ovarian Cancers With 60 Patients Each

THOMSON REUTERS

Propanc Biopharma engages European CDMO for GMP production of PRP therapy

Propanc Biopharma Inc trading halted, news pending

Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results

THOMSON REUTERS

Propanc Biopharma Q3 EPS $(0.28) Up From $(12.50) YoY

Benzinga Earnings

Propanc Biopharma Q3 FY26 net loss narrows to USD 6.36 million; no revenue

Propanc Biopharma announces 1-for-25 reverse stock split

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/PPCB/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PPCB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPCB\",,,,,undefined,":{"symbol":"PPCB","market":"US","secType":"STK","nameCN":"Propanc Biopharma, Inc.","latestPrice":1.35,"timestamp":1787947200000,"preClose":2.23,"halted":0,"volume":4056907,"hourTrading":{"tag":"盘后","latestPrice":1.34,"preClose":1.35,"latestTime":"19:59 EDT","volume":171742,"amount":233336.6944,"timestamp":1787961596407,"change":-0.01,"changeRate":-0.007407,"amplitude":0.059259},"delay":0,"changeRate":-0.39461883408071746,"floatShares":1250100,"shares":3503100,"eps":-32.455997,"marketStatus":"Market Closed","change":-0.88,"latestTime":"08-28 16:00:00 EDT","open":1.93,"high":1.94,"low":1.31,"amount":6737787.0097609,"amplitude":0.282511,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-32.455997,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788163200000},"marketStatusCode":7,"adr":0,"listingDate":1743998400000,"exchange":"NASDAQ","adjPreClose":2.23,"preHourTrading":{"tag":"盘前","latestPrice":1.93,"preClose":2.23,"latestTime":"09:29 EDT","volume":426163,"amount":790519.3670285,"timestamp":1787923799094,"change":-0.3,"changeRate":-0.134529,"amplitude":0.233139},"postHourTrading":{"tag":"盘后","latestPrice":1.34,"preClose":1.35,"latestTime":"19:59 EDT","volume":171742,"amount":233336.6944,"timestamp":1787961596407,"change":-0.01,"changeRate":-0.007407,"amplitude":0.059259},"volumeRatio":0.20828084265249786},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPCB\",,,,,undefined,":{"symbol":"PPCB","floatShares":1250100,"roa":"-62.31%","roe":"-126.98%","lyrEps":-371.224075,"volumeRatio":0.20828084265249786,"shares":3503100,"dividePrice":0,"high":1.94,"amplitude":0.282511,"preClose":2.23,"low":1.31,"week52Low":0.95,"pbRate":"0.48","week52High":81,"institutionHeld":0,"latestPrice":1.35,"eps":-32.455997,"divideRate":0,"volume":4056907,"delay":0,"ttmEps":-32.455997,"open":1.93,"prevYearClose":13.415,"prevWeekClose":1.08,"prevMonthClose":1.01,"prevQuarterClose":1.5,"fiveDayClose":1.08,"twentyDayClose":1.01,"sixtyDayClose":1.635},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PPCB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-18","symbol":"PPCB","defaultRemindTime":1779111000000,"type":"split","dateTimestamp":1779076800000,"forFactor":25,"toFactor":1,"ratio":25},{"market":"US","date":"2025-01-29","symbol":"PPCB","defaultRemindTime":1738161000000,"type":"split","dateTimestamp":1738126800000,"forFactor":60000,"toFactor":1,"ratio":60000},{"market":"US","date":"2023-05-23","symbol":"PPCB","defaultRemindTime":1684848600000,"type":"split","dateTimestamp":1684814400000,"forFactor":1000,"toFactor":1,"ratio":1000},{"market":"US","date":"2020-11-19","symbol":"PPCB","defaultRemindTime":1605796200000,"type":"split","dateTimestamp":1605762000000,"forFactor":1000,"toFactor":1,"ratio":1000},{"market":"US","date":"2019-06-24","symbol":"PPCB","type":"split","dateTimestamp":1561348800000,"forFactor":500,"toFactor":1,"ratio":500}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PPCB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PPCB\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PPCB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PPCB","date":"2026-08-28","current":-0.041595,"percent":0.20229,"low":-1.336323,"twenty":-0.28152,"median":-0.125329,"eighty":-0.041146,"high":-0.023125,"avg":-0.18284,"sd":0.194072,"marketCap":5080767},"quantilePoints":[{"date":"2025-04-04","current":-0.050633,"twenty":-0.050633,"median":-0.050633,"eighty":-0.050633,"marketCap":84546},{"date":"2025-04-07","current":-0.048332,"twenty":-0.050633,"median":-0.050633,"eighty":-0.049713,"marketCap":80703},{"date":"2025-08-22","current":-0.938461,"twenty":-0.969897,"median":-0.655598,"eighty":-0.050633,"marketCap":51812834},{"date":"2025-08-29","current":-0.721182,"twenty":-0.884372,"median":-0.710781,"eighty":-0.050633,"marketCap":39816759},{"date":"2025-09-05","current":-0.457673,"twenty":-0.820575,"median":-0.688821,"eighty":-0.213449,"marketCap":25268328},{"date":"2025-09-12","current":-0.457673,"twenty":-0.778969,"median":-0.631034,"eighty":-0.41283,"marketCap":25268328},{"date":"2025-09-19","current":-0.506214,"twenty":-0.755854,"median":-0.517772,"eighty":-0.439644,"marketCap":27948302},{"date":"2025-09-26","current":-0.418378,"twenty":-0.712861,"median":-0.510837,"eighty":-0.435021,"marketCap":23098825},{"date":"2025-10-03","current":-0.399917,"twenty":-0.699454,"median":-0.498124,"eighty":-0.407301,"marketCap":23564414},{"date":"2025-10-10","current":-0.408611,"twenty":-0.69067,"median":-0.457673,"eighty":-0.403395,"marketCap":24076684},{"date":"2025-10-17","current":-0.343407,"twenty":-0.669984,"median":-0.449583,"eighty":-0.385572,"marketCap":20234660},{"date":"2025-10-24","current":-0.321672,"twenty":-0.645772,"median":-0.432247,"eighty":-0.369488,"marketCap":18953985},{"date":"2025-10-31","current":-0.269509,"twenty":-0.610693,"median":-0.4245,"eighty":-0.343407,"marketCap":15880366},{"date":"2025-11-07","current":-0.241906,"twenty":-0.556142,"median":-0.418378,"eighty":-0.313847,"marketCap":14253909},{"date":"2025-11-14","current":-0.169965,"twenty":-0.518234,"median":-0.404264,"eighty":-0.269509,"marketCap":10014876},{"date":"2025-11-21","current":-0.174454,"twenty":-0.514536,"median":-0.397743,"eighty":-0.234995,"marketCap":11061584},{"date":"2025-11-28","current":-0.188344,"twenty":-0.512687,"median":-0.384703,"eighty":-0.189884,"marketCap":11942288},{"date":"2025-12-05","current":-0.173885,"twenty":-0.509912,"median":-0.372748,"eighty":-0.182127,"marketCap":11025501},{"date":"2025-12-12","current":-0.170028,"twenty":-0.504827,"median":-0.356448,"eighty":-0.174606,"marketCap":10780935},{"date":"2025-12-19","current":-0.151754,"twenty":-0.498818,"median":-0.343407,"eighty":-0.171335,"marketCap":9622255},{"date":"2025-12-26","current":-0.139108,"twenty":-0.496968,"median":-0.326019,"eighty":-0.170682,"marketCap":8820401},{"date":"2026-01-02","current":-0.113099,"twenty":-0.476627,"median":-0.315152,"eighty":-0.168873,"marketCap":7171266},{"date":"2026-01-09","current":-0.101254,"twenty":-0.460447,"median":-0.284723,"eighty":-0.163023,"marketCap":6420182},{"date":"2026-01-16","current":-0.074044,"twenty":-0.457673,"median":-0.262988,"eighty":-0.151375,"marketCap":4694858},{"date":"2026-01-23","current":-0.056065,"twenty":-0.453513,"median":-0.243754,"eighty":-0.138341,"marketCap":3554888},{"date":"2026-01-30","current":-0.058573,"twenty":-0.449352,"median":-0.223866,"eighty":-0.121547,"marketCap":3713923},{"date":"2026-02-06","current":-0.042554,"twenty":-0.442879,"median":-0.192195,"eighty":-0.107345,"marketCap":2698240},{"date":"2026-02-13","current":-0.048688,"twenty":-0.435021,"median":-0.182701,"eighty":-0.093848,"marketCap":3087140},{"date":"2026-02-20","current":-0.048657,"twenty":-0.431486,"median":-0.176899,"eighty":-0.077306,"marketCap":3214676},{"date":"2026-02-27","current":-0.046857,"twenty":-0.428606,"median":-0.174834,"eighty":-0.060466,"marketCap":3095731},{"date":"2026-03-06","current":-0.040376,"twenty":-0.424799,"median":-0.173681,"eighty":-0.05647,"marketCap":2667530},{"date":"2026-03-13","current":-0.029045,"twenty":-0.422077,"median":-0.17085,"eighty":-0.050499,"marketCap":1918972},{"date":"2026-03-20","current":-0.028085,"twenty":-0.419765,"median":-0.170682,"eighty":-0.048484,"marketCap":1855535},{"date":"2026-03-27","current":-0.034166,"twenty":-0.417079,"median":-0.169454,"eighty":-0.047319,"marketCap":2257270},{"date":"2026-04-02","current":-0.035336,"twenty":-0.413827,"median":-0.167383,"eighty":-0.04606,"marketCap":2334602},{"date":"2026-04-10","current":-0.031762,"twenty":-0.406872,"median":-0.16427,"eighty":-0.043866,"marketCap":2098425},{"date":"2026-04-17","current":-0.033628,"twenty":-0.399911,"median":-0.155654,"eighty":-0.041322,"marketCap":2221738},{"date":"2026-04-24","current":-0.036697,"twenty":-0.399457,"median":-0.149858,"eighty":-0.040438,"marketCap":2424475},{"date":"2026-05-01","current":-0.032141,"twenty":-0.39557,"median":-0.138149,"eighty":-0.039889,"marketCap":2123505},{"date":"2026-05-08","current":-0.029421,"twenty":-0.386441,"median":-0.123469,"eighty":-0.037064,"marketCap":1943760},{"date":"2026-05-15","current":-0.023125,"twenty":-0.382964,"median":-0.117367,"eighty":-0.035899,"marketCap":1527837},{"date":"2026-05-22","current":-0.078772,"twenty":-0.376009,"median":-0.107725,"eighty":-0.036443,"marketCap":1446323},{"date":"2026-05-29","current":-0.077406,"twenty":-0.376009,"median":-0.101254,"eighty":-0.036697,"marketCap":1421242},{"date":"2026-06-05","current":-0.075584,"twenty":-0.369488,"median":-0.094421,"eighty":-0.037013,"marketCap":1387801},{"date":"2026-06-12","current":-0.110645,"twenty":-0.369488,"median":-0.091369,"eighty":-0.037013,"marketCap":2031540},{"date":"2026-06-18","current":-0.077861,"twenty":-0.359056,"median":-0.091369,"eighty":-0.037215,"marketCap":1429602},{"date":"2026-06-26","current":-0.068755,"twenty":-0.347754,"median":-0.088611,"eighty":-0.037494,"marketCap":1262397},{"date":"2026-07-02","current":-0.178687,"twenty":-0.344276,"median":-0.088611,"eighty":-0.038576,"marketCap":3280854},{"date":"2026-07-10","current":-0.220877,"twenty":-0.343407,"median":-0.091369,"eighty":-0.03962,"marketCap":4055500},{"date":"2026-07-17","current":-0.1973,"twenty":-0.335582,"median":-0.096459,"eighty":-0.039946,"marketCap":3622609},{"date":"2026-07-24","current":-0.179928,"twenty":-0.32515,"median":-0.101254,"eighty":-0.040156,"marketCap":3303637},{"date":"2026-07-31","current":-0.129051,"twenty":-0.321672,"median":-0.106776,"eighty":-0.040305,"marketCap":2369505},{"date":"2026-08-07","current":-0.16876,"twenty":-0.316456,"median":-0.111872,"eighty":-0.040388,"marketCap":3098584},{"date":"2026-08-14","current":-0.151387,"twenty":-0.306023,"median":-0.120497,"eighty":-0.04047,"marketCap":2779612},{"date":"2026-08-21","current":-0.136497,"twenty":-0.295156,"median":-0.123158,"eighty":-0.040781,"marketCap":2506208},{"date":"2026-08-28","current":-0.276716,"twenty":-0.28152,"median":-0.125329,"eighty":-0.041146,"marketCap":5080767}],"updateTime":1788116628544},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PPCB\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2649987716","title":"Propanc Biopharma - Mou to Support Phase 1B First-in-human Trial for Propanc's Prp","url":"https://stock-news.laohu8.com/highlight/detail?id=2649987716","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649987716?lang=en_us&edition=fundamental","pubTime":"2026-07-07 20:30","pubTimestamp":1783427402,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUA4WFN1F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649877469","title":"Propanc Biopharma Signs Mou with Avance Clinical Pty Ltd","url":"https://stock-news.laohu8.com/highlight/detail?id=2649877469","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649877469?lang=en_us&edition=fundamental","pubTime":"2026-07-07 20:30","pubTimestamp":1783427402,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUA4WFN1F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648507485","title":"Propanc Biopharma Initiates $5.0 Million Share Repurchase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2648507485","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648507485?lang=en_us&edition=fundamental","pubTime":"2026-07-02 20:30","pubTimestamp":1782995400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nTUA8RDFQR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643768348","title":"Propanc CEO visits European manufacturer ahead of drug production plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2643768348","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643768348?lang=en_us&edition=fundamental","pubTime":"2026-06-16 21:41","pubTimestamp":1781617271,"startTime":"0","endTime":"0","summary":"Propanc Biopharma (PPCB) announced that CEO James Nathanielsz toured a European contract development and manufacturing organization’s facility in p...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/propanc-ceo-visits-european-manufacturer-ahead-of-drug-production-plan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/propanc-ceo-visits-european-manufacturer-ahead-of-drug-production-plan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EPV","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643757305","title":"Propanc Biopharma CEO tours European CDMO GMP facility ahead of PRP production for Phase 1b study","url":"https://stock-news.laohu8.com/highlight/detail?id=2643757305","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643757305?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:45","pubTimestamp":1781613920,"startTime":"0","endTime":"0","summary":"Propanc Biopharma CEO James Nathanielsz toured a European CDMO’s GMP facility to prepare for PRP production tied to its Phase 1b first-in-human study.Propanc aligned project timelines with the manufacturer, targeting preproduction in August 2026, an engineering run in October 2026, GMP manufacture from December 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL33tlpf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","IE00BN0W2T93.GBP","LU0314104364.USD","SG9999014039.USD","BK4585","LU2210149790.SGD","BK4139","PPCB","IE00BN0W2V16.EUR","BK4112","BK4588","IE00B64PRP62.GBP","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU2095319765.USD","NDAQ","SG9999014005.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642366802","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2642366802","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642366802?lang=en_us&edition=fundamental","pubTime":"2026-06-12 01:37","pubTimestamp":1781199431,"startTime":"0","endTime":"0","summary":"Propanc Biopharma  approved a share repurchase program to buy back up to $5 million of common stock, the company said Thursday.Shares soared 124% as intraday trading volume catapulted to over 155.6 million from a daily average of about 130,000.Adial Pharmaceuticals  said Thursday it has acquired Azora Therapeutics, a biopharmaceutical company developing treatments for serious inflammatory diseases.Shares soared 30% amid a surge in intraday trading volume to over 16.5 million from a daily average of roughly 118,000.Applied Materials  expanded manufacturing and research & development operations in Singapore with a $500 million facility in Tampines to support AI-driven semiconductor demand.Shares jumped 8.5% following an increase in intraday trading volume to over 5.3 million from a daily average of about 7 million.Price: 3.04, Change: +1.69, Percent Change: +124.81","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BSNM7G36.USD","LU0198837287.USD","IE00BD6J9T35.USD","LU0354030511.USD","LU1674673428.USD","BK4518","LU0661504455.SGD","LU2089985449.USD","LU1069344957.HKD","LU1003077747.HKD","LU2111349929.HKD","LU1917777945.USD","LU0061475181.USD","LU1868836591.USD","BK4588","LU1989773731.SGD","LU1868837136.USD","LU0175139822.USD","ADIL","LU1823568750.SGD","LU2028103732.USD","LU1989763005.USD","LU0957808578.USD","IE0009356076.USD","LU0868494708.USD","LU0942090050.USD","LU2413666426.HKD","AMAT","LU2413666699.HKD","LU1815333072.USD","LU0444971666.USD","LU2458330169.SGD","IE00BQXX3D17.EUR","LU1778281490.HKD","BK4585","LU1721428933.USD","LU1868836757.USD","LU1674673691.USD","BK4567","BK4147","LU1267930813.SGD","LU0158827948.USD","SG9999002232.USD","LU2458330243.SGD","LU1046421795.USD","LU0738911758.USD","LU2089284900.SGD","LU0096362180.USD","PPCB","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642280969","title":"Propanc Biopharma Authorizes $5 Million Stock Buyback Program; Shares Jump","url":"https://stock-news.laohu8.com/highlight/detail?id=2642280969","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642280969?lang=en_us&edition=fundamental","pubTime":"2026-06-11 22:07","pubTimestamp":1781186851,"startTime":"0","endTime":"0","summary":"Propanc Biopharma  said Thursday it approved a share repurchase program allowing it to buy back up to $5 million of its common stock.Under the program, Propanc Biopharma may repurchase shares from time to time in amounts, at prices and at times it deems appropriate, subject to market conditions, the company said.Propanc said the company \"is entering a transformative stage with a novel, first-in-class cancer therapy for treatment & prevention of metastatic cancer from solid tumors.\"Propanc Biopharma shares were more than 250% higher in Thursday trading.Price: 5.33, Change: +3.98, Percent Change: +294.81","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642849442","title":"Propanc Biopharma launches USD 5 million share buyback program","url":"https://stock-news.laohu8.com/highlight/detail?id=2642849442","media":"Reuters","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642849442?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:31","pubTimestamp":1781181100,"startTime":"0","endTime":"0","summary":"Propanc Biopharma authorized a share repurchase program of up to USD 5 million of common stock.Buybacks may be executed from time to time, depending on market conditions, with no required minimum share count.The program can be modified, suspended, or terminated at any time.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL4F7gyL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","LU2210149790.SGD","LU2095319765.USD","SG9999014005.SGD","PPCB","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014039.USD","BK4585","LU2210150020.SGD","IE00BGHQF748.EUR","BK4112","SG9999014013.SGD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","SG9999014021.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642284645","title":"Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2642284645","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642284645?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:30","pubTimestamp":1781181000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nTUA9604P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642286454","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2642286454","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642286454?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:00","pubTimestamp":1781175643,"startTime":"0","endTime":"0","summary":"Galaxy Payroll Group  shares were up 324% in Thursday premarket activity, recovering from a 5.2% loss in the earlier session.CCH  stock was 148% higher following a largely muted Wednesday session.Propanc Biopharma  shares were up 132%, reversing from a 2.2% loss in the previous session.UTime  stock was 73% higher, following a muted Wednesday session.Quhuo  shares were up 68%, recovering from a 5% decline in the earlier session.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GLXG","BK4139","BK4137","BK4130","PPCB","BK4145","BK4539","WTO","BK4209","CCHH","QH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640199489","title":"Propanc Biopharma CEO attends University of Granada keynote on rejuvenation science","url":"https://stock-news.laohu8.com/highlight/detail?id=2640199489","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640199489?lang=en_us&edition=fundamental","pubTime":"2026-06-02 17:30","pubTimestamp":1780392616,"startTime":"0","endTime":"0","summary":"Propanc CEO James Nathanielsz attended a University of Granada keynote on rejuvenation science in Granada, Spain.He highlighted Propanc’s proenzyme research with Granada and Jaén universities as PRP targets a Phase 1b first-in-human trial in advanced cancer.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL5YzzDn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BN0W2T93.GBP","BK4585","NDAQ","LU2095319765.USD","BK4112","SG9999014021.USD","IE00BKPKM429.USD","LU2210150020.SGD","BK4139","BK4588","SG9999014039.USD","SG9999014013.SGD","LU2210149790.SGD","LU0314104364.USD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","PPCB","SG9999014005.SGD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636784703","title":"Propanc Biopharma plans Phase 1b first-in-human PRP trial in Australia in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2636784703","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636784703?lang=en_us&edition=fundamental","pubTime":"2026-05-20 21:04","pubTimestamp":1779282277,"startTime":"0","endTime":"0","summary":"Propanc Biopharma on May 20, 2026 outlined plans to start a first-in-human Phase 1b study of its PRP drug candidate in 30-40 advanced solid-tumor patients later this year, with results to be presented in the future.The trial is designed to assess safety and tolerability for a higher-dose, once-weekly intravenous formulation, marking a shift from earlier compassionate-use dosing.Prior compassionate-use findings were already published, with patients exceeding expected survival and no severe side effects reported.The company expects Phase 1b to support subsequent Phase 2 studies in pancreatic cancer and ovarian cancer to test whether PRP can show clinical benefit in those settings.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Bi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL49cDQd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636847826","title":"Propanc Biopharma Inc - to File Cta in Australia for Phase 1B Study in 30–40 Advanced Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2636847826","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636847826?lang=en_us&edition=fundamental","pubTime":"2026-05-20 20:45","pubTimestamp":1779281151,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nFWN41X0G4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636829847","title":"Propanc Biopharma Inc - Plans Two Phase 2 Studies in Pancreatic and Ovarian Cancers With 60 Patients Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2636829847","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636829847?lang=en_us&edition=fundamental","pubTime":"2026-05-20 20:45","pubTimestamp":1779281151,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nFWN41X0G4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636593859","title":"Propanc Biopharma engages European CDMO for GMP production of PRP therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2636593859","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636593859?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:45","pubTimestamp":1779194716,"startTime":"0","endTime":"0","summary":"Propanc Biopharma engaged a Europe-based contract development and manufacturing organization to produce GMP-grade PRP for a planned Phase 1b first-in-human trial.Manufacturing is intended to support a 30-40 patient study in advanced solid-tumor cancers, with a clinical trial application targeted for filing later this year.PRP is designed for once-weekly intravenous dosing, with the study expected to test significantly higher doses than prior compassionate-use experience cited by the company.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL3bwKYF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4139","IE00BN0W2T93.GBP","LU0314104364.USD","NDAQ","IE00BN0W2W23.USD","IE00B64PRP62.GBP","BK4585","BK4112","LU2210149790.SGD","SG9999014039.USD","IE00BN0W2V16.EUR","SG9999014013.SGD","PPCB","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","SG9999014021.USD","BK4588","LU2095319765.USD","IE00BKPKM429.USD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635166056","title":"Propanc Biopharma Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2635166056","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635166056?lang=en_us&edition=fundamental","pubTime":"2026-05-16 07:51","pubTimestamp":1778889061,"startTime":"0","endTime":"0","summary":"19:50 EDT Propanc Biopharma (PPCB) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving br...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-inc-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-inc-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635082911","title":"Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635082911","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635082911?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:45","pubTimestamp":1778849100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nTUA991Z07:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635472166","title":"Propanc Biopharma Q3 EPS $(0.28) Up From $(12.50) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2635472166","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635472166?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:33","pubTimestamp":1778794381,"startTime":"0","endTime":"0","summary":"Propanc Biopharma (NASDAQ:PPCB) reported quarterly losses of $(0.28) per share. This is a 97.76 percent increase over losses of $(12.50) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52584937/propanc-biopharma-q3-eps-0-28-up-from-12-50-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Propanc Biopharma Q3 EPS $(0.28) Up From $(12.50) YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QLD","NVIW.SI","IYW","QID","FTEC","QQQY","BK4139","PPCB","QDTE","QQQJ","QQQA","PSQ","SQQQ","MNQmain","NQmain","QQQM","JEPQ","TQQQ","NDX","QQQE","TQQY","TECS",".IXIC","ONEQ","QQQ","QYLG","GPIQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635721507","title":"Propanc Biopharma Q3 FY26 net loss narrows to USD 6.36 million; no revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2635721507","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635721507?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:31","pubTimestamp":1778794274,"startTime":"0","endTime":"0","summary":"Propanc Biopharma posted a net loss of USD 6.36 million for the quarter ended March 31, 2026, narrowing from USD 54.07 million a year earlier.Administration expense fell to USD 6.22 million from USD 53.07 million, primarily due to lower stock-based compensation and stock-based consulting costs.Research and development expense rose to USD 169,660 from USD 54,097 as work advanced on PRP toward a Phase 1b first-in-human study in 30-40 advanced solid-tumor patients.Cash totaled USD 443,702 at March 31, 2026, down from USD 12.09 million at June 30, 2025; net cash used in operating activities was USD 4.08 million for the nine months ended March 31, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the orig","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL1p2Vzq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635188627","title":"Propanc Biopharma announces 1-for-25 reverse stock split","url":"https://stock-news.laohu8.com/highlight/detail?id=2635188627","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635188627?lang=en_us&edition=fundamental","pubTime":"2026-05-14 17:34","pubTimestamp":1778751248,"startTime":"0","endTime":"0","summary":"Propanc Biopharma (PPCB) announced that its board of directors on March 16 approved a 1-for-25 reverse stock split of the company’s issued and outs...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-announces-1-for-25-reverse-stock-split-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-announces-1-for-25-reverse-stock-split-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":60,"code":"91000000","status":"200"}]}}